Ignite Creation Date:
2024-05-05 @ 6:51 PM
Last Modification Date:
2024-10-26 @ 9:37 AM
Study NCT ID:
NCT00556699
Status:
COMPLETED
Last Update Posted:
2014-03-20
First Post:
2007-11-09
Brief Title:
A Study of SGN-40 in Combination With Rituximab in Patients With CD20-Positive Follicular and Marginal Zone B-Cell Non-Hodgkins Lymphoma
Sponsor:
Genentech Inc
Organization:
Genentech Inc
Study Overview
Official Title:
An Open-Label Phase Ib Study of the Safety Pharmacokinetics and Activity of the Anti-CD40 Monoclonal Antibody SGN-40 Administered in Combination With Rituximab in Patients With CD20-Positive Follicular and Marginal Zone B-Cell Non-Hodgkins Lymphoma Who Have Relapsed Following Previous Rituximab Therapy
Status:
COMPLETED
Status Verified Date:
2011-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is an open-label multicenter Phase Ib study designed to evaluate the safety pharmacokinetics and preliminary efficacy of SGN-40 when combined with rituximab in patients with relapsed CD20-positive follicular or marginal zone NHL who have received at least one prior rituximab-containing regimen
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None